SCN1A

Chr 2AD

sodium voltage-gated channel alpha subunit 1

Also known as: DEE6, DEE6A, DEE6B, DRVT, EIEE6, FEB3, FEB3A, FHM3

Voltage-dependent sodium channels are heteromeric complexes that regulate sodium exchange between intracellular and extracellular spaces and are essential for the generation and propagation of action potentials in muscle cells and neurons. Each sodium channel is composed of a large pore-forming, glycosylated alpha subunit and two smaller beta subunits. This gene encodes a sodium channel alpha subunit, which has four homologous domains, each of which contains six transmembrane regions. Allelic variants of this gene are associated with generalized epilepsy with febrile seizures and epileptic encephalopathy. Alternative splicing results in multiple transcript variants. The RefSeq Project has decided to create four representative RefSeq records. Three of the transcript variants are supported by experimental evidence and the fourth contains alternate 5' untranslated exons, the exact combination of which have not been experimentally confirmed for the full-length transcript. [provided by RefSeq, Oct 2015]

Primary Disease Associations & Inheritance

Developmental and epileptic encephalopathy 6B, non-DravetMIM #619317
AD
Dravet syndromeMIM #607208
AD
Febrile seizures, familial, 3AMIM #604403
AD
Generalized epilepsy with febrile seizures plus, type 2MIM #604403
AD
Migraine, familial hemiplegic, 3MIM #609634
AD
UniProtIntractable childhood epilepsy with generalized tonic-clonic seizures
600
ClinVar variants
199
Pathogenic / LP
1.00
pLI score· haploinsufficient
8
Active trials
Clinical SummarySCN1A
🧬
Gene-Disease Validity (ClinGen)
generalized epilepsy with febrile seizures plus · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

4 total gene-disease associations curated

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
199 Pathogenic / Likely Pathogenic· 278 VUS of 600 total submissions
💊
Clinical Trials
8 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Dual constrained — LoF & missense intolerant
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.07LOEUF
pLI 1.000
Z-score 8.52
OE 0.02 (0.010.07)
Highly constrained

Among the most LoF-intolerant genes (~top 3%)

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
5.22Z-score
OE missense 0.55 (0.510.59)
590 obs / 1070.7 exp
Constrained

Extremely missense-constrained (top ~0.01%)

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.02 (0.010.07)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.0.55 (0.510.59)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.0.94
01.21.6
LoF obs/exp: 2 / 88.5Missense obs/exp: 590 / 1070.7Syn Z: 0.88

ClinVar Variant Classifications

600 submitted variants in ClinVar

Classification Summary

Pathogenic105
Likely Pathogenic94
VUS278
Likely Benign110
Benign8
Conflicting5
105
Pathogenic
94
Likely Pathogenic
278
VUS
110
Likely Benign
8
Benign
5
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
34
32
39
0
105
Likely Pathogenic
21
65
8
0
94
VUS
3
232
39
4
278
Likely Benign
0
2
41
67
110
Benign
0
0
6
2
8
Conflicting
5
Total5833113373600

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

SCN1A · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Gene2Phenotype Curations

SCN1A-related seizure disorders

definitive
ADLoss Of FunctionAbsent Gene Product
Dev. Disorders
G2P ↗

Gene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

Developmental and epileptic encephalopathy 6B, non-Dravet

MIM #619317

Molecular basis of disorder known

Autosomal dominant

Dravet syndrome

MIM #607208

Molecular basis of disorder known

Autosomal dominant

Febrile seizures, familial, 3A

MIM #604403

Molecular basis of disorder known

Autosomal dominant

Generalized epilepsy with febrile seizures plus, type 2

MIM #604403

Molecular basis of disorder known

Autosomal dominant

Migraine, familial hemiplegic, 3

MIM #609634

Molecular basis of disorder known

Autosomal dominant
📖
GeneReview available — SCN1A
Authoritative clinical overview · NCBI Bookshelf · Recommended first read
Open GeneReview ↗
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
SCN1A-related phenotypes: Epilepsy and beyond.
Scheffer IE et al.·Epilepsia
2019Review
State-of-the-art management of Dravet syndrome.
Vasquez A et al.·Dev Med Child Neurol
2025Review
Familial hemiplegic migraine.
Villar-Martinez MD et al.·Handb Clin Neurol
2024Review
Epilepsies.
McTague A et al.·Handb Clin Neurol
2024Review
Top 10 resultsSearch PubMed ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Dravet Syndrome

Longitudinal Study of Phenotypic and Developmental Severity in Patients With Dravet Syndrome With SCN1A Gene Mutation

RECRUITING
NCT07251673Assistance Publique - Hôpitaux de ParisStarted 2025-09-15
Dravet SyndromeEpilepsy

Neurodevelopmental Impact of Epilepsy on Autonomic Function in Dravet Syndrome

ACTIVE NOT RECRUITING
NCT05472389Phase NAHospices Civils de LyonStarted 2022-10-14
Video-electroencephalographyBlood Samples
16P11.2 Deletion Syndrome16p11.2 Duplications1Q21.1 Deletion

Online Study of People Who Have Genetic Changes and Features of Autism: Simons Searchlight

RECRUITING
NCT01238250Simons SearchlightStarted 2010-10
Dravet Syndrome

A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome

ACTIVE NOT RECRUITING
NCT06283212Phase PHASE1, PHASE2Encoded TherapeuticsStarted 2024-05-09
ETX101
Dravet Syndrome

A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome

RECRUITING
NCT05419492Phase PHASE1, PHASE2Encoded TherapeuticsStarted 2024-05-14
ETX101
EpilepsyDravet SyndromeDrug Resistant Epilepsy

A PET-MRI Study of Serotoninergic Brainstem Pathway in Patients With Dravet Syndrome

NOT YET RECRUITING
NCT07013331Phase NAHospices Civils de LyonStarted 2026-04-01
[18F]MPPF PET-MRI
Dravet Syndrome

A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome (Australia Only)

ACTIVE NOT RECRUITING
NCT06112275Phase PHASE1, PHASE2Encoded TherapeuticsStarted 2024-02-28
ETX101
Dravet Syndrome

EXploring novEl Molecular Determinants of DRAvet Syndrome Phenotype Heterogeneity

ENROLLING BY INVITATION
NCT06371794Phase NAFondazione Policlinico Universitario Agostino Gemelli IRCCSStarted 2023-07-06
skin punch biopsy